Coagulation Factor IX for Hemophilia B Therapy

被引：27
|
作者：
Orlova, N. A. [1 ,2 ]
Kovnir, S. V. [1 ,2 ]
Vorobiev, I. I. [1 ,2 ]
Gabibov, A. G. [1 ]
机构：
[1] Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
[2] Minist Healthcare & Social Dev Russian Federat, Hematol Res Ctr, Moscow 125167, Russia
来源：
ACTA NATURAE | 2012年 / 4卷 / 02期
关键词：
coagulation factor IX; hemophilia B; heterologous protein expression systems; CLOTTING FACTOR-IX; RECOMBINANT FACTOR-IX; SUSTAINED PHENOTYPIC CORRECTION; PREVIOUSLY TREATED PATIENTS; MEDIATED GENE-TRANSFER; LONG-TERM CORRECTION; HUMAN PROTEIN-C; FACTOR-X; PHARMACOKINETIC PROPERTIES; STRUCTURAL-ANALYSIS;
D O I：
10.32607/20758251-2012-4-2-62-73
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires constant protein replacement therapy. Reviewed herein are the current state in the manufacturing of FIX, improved variants of the recombinant protein for therapy, transgenic organisms for obtaining FIX, and the advances in the gene therapy of hemophilia B.
引用
收藏
页码：62 / 73
页数：12
相关论文
共 50 条
  • [21] ORAL PROPHYLACTIC THERAPY IN HEMOPHILIA-A AND HEMOPHILIA-B (FACTOR-VIII AND FACTOR-IX DEFICIENCIES)
    STAPP, WF
    BOUDREAUX, HB
    THROMBOSIS AND HAEMOSTASIS, 1977, 38 (01) : 384 - 384
  • [22] Pharmacokinetic/Pharmacodynamic Assessment of Reformulated Recombinant Coagulation Factor IX in Adults and Children with Severe Hemophilia B
    Korth-Bradley, J. M.
    Valentino, Leonard A.
    Rendo, Pablo
    Shafer, Frank E.
    Smith, Lynne
    Baumann, James A.
    Charnigo, Robert
    BLOOD, 2011, 118 (21) : 536 - 537
  • [23] FACTOR-IX ACTIVITY AND FACTOR-IX ANTIGEN IN HEMOPHILIA B CARRIERS
    ELODI, S
    THROMBOSIS RESEARCH, 1975, 6 (01) : 39 - 51
  • [24] A case of severe hemophilia B associated with a large insertion of SVA RETROTRANSPOSON in the coagulation factor IX gene
    Mizutani, N.
    Nakamura, Y.
    Murata, M.
    Takagi, Y.
    Hasebe, R.
    Kozuka, T.
    Nakata, Y.
    Takagi, A.
    Kitazawa, J-, I
    Shima, M.
    Kojima, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 317 - 317
  • [25] TREATMENT OF HEMOPHILIA-B - SERENDIPITOUS USE OF CONTINUOUS-INFUSION COAGULATION FACTOR-IX
    GOLDSMITH, JC
    GORDON, EM
    THROMBOSIS RESEARCH, 1993, 70 (03) : 265 - 267
  • [26] Factor IX immunogenicity in hemophilia B patients on replacement therapy with a recombinant factor IX investigational product (IB1001)
    Drobic, B.
    Hua, Y.
    Babinchak, T.
    Gomperts, E.
    Hall, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 323 - 323
  • [27] STUDIES OF FACTOR-IX CONCENTRATE THERAPY IN HEMOPHILIA
    HULTIN, MB
    BLOOD, 1983, 62 (03) : 677 - 684
  • [28] FACTOR-IX ANTIGEN BY RADIOIMMUNOASSAY - ABNORMAL FACTOR-IX PROTEIN IN PATIENTS ON WARFARIN THERAPY AND WITH HEMOPHILIA-B
    THOMPSON, AR
    JOURNAL OF CLINICAL INVESTIGATION, 1977, 59 (05): : 900 - 910
  • [29] A HIGHLY PURIFIED HUMAN FACTOR-IX CONCENTRATE FOR THE THERAPY OF HEMOPHILIA-B
    SUOMELA, H
    HAMALAINEN, E
    AHO, L
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1158 - 1158
  • [30] Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
    George, L. A.
    Sullivan, S. K.
    Giermasz, A.
    Rasko, J. E. J.
    Samelson-Jones, B. J.
    Ducore, J.
    Cuker, A.
    Sullivan, L. M.
    Majumdar, S.
    Teitel, J.
    McGuinn, C. E.
    Ragni, M. V.
    Luk, A. Y.
    Hui, D.
    Wright, J. F.
    Chen, Y.
    Liu, Y.
    Wachtel, K.
    Winters, A.
    Tiefenbacher, S.
    Arruda, V. R.
    van der Loo, J. C. M.
    Zelenaia, O.
    Takefman, D.
    Carr, M. E.
    Couto, L. B.
    Anguela, X. M.
    High, K. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (23): : 2215 - 2227
12345